米氮平治疗失眠症的临床观察

Mirtazapine clinical observation for the treatment of insomnia

目的 探讨米氮平对失眠症患者的治疗效果及安全性?方法采用随机对照方法,将92例失眠症患者随机分为米氮平组和阿普唑仑组,疗程为4周,使用匹兹堡睡眠质量指数(pittsburgh sleep quality index,PSQI)?汉密尔顿焦虑量表(Hamilton anxiety scale,HAMA)?汉密尔顿抑郁量表(Hamilton depression rating scale,HAMD)评定疗效;副反应量表评定副反应?结果米氮平组在治疗第4周时PSQI总分?HAMA?HAMD分别为(6.1±2.3)分?(5.9±3.1)分?(12.1±5.9)分,明显优于阿普唑仑组(7.2±3)分?(9±4.9)分?(17.1±5.8)分,差异具有统计学意义(P<0.01)?结论与阿普唑仑相比,米氮平不仅能显著改善失眠症患者的睡眠状况,而且可以明显减少患者日常功能的缺失?

Objective To evaluate the effect of mirtazapine in the treatment of insomnia. Methods 92 cases of insomnia patients were randomly divided into mirtazapine group（n=46） and alprazolam group（n=46）. The period of treatment was 4 weeks. The efficacy and side effects were evaluated by Pittsburgh Sleep Quality Index （PSQI）,Hamilton Anxiety Scale,Hamilton Depression Rating Scale and Treatment Emergent Symptom Scale（TESS）. Results The PSQI total score, HAMA and HAMD after 4 weeks treatment in mirtazapine group were（6.1±2.3）,（5.9±3.1）and（12.1±5.9）and significantly superior to（7.2±3）,（9±4.9）and （17.1±5.8）in alprazolam group respectively,there were statistically significant differences（P〈0.01）. Conclusions Compared with alprazolam,mirtazapine not only can significantly improve sleep status,but also can significantly reduce the daily function missing in the patients with insomnia.